61 related articles for article (PubMed ID: 26871940)
1. Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure-Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program.
Zhang T; Liu Y; Yang X; Martin GE; Yao H; Shang J; Bugianesi RM; Ellsworth KP; Sonatore LM; Nizner P; Sherer EC; Hill SE; Knemeyer IW; Geissler WM; Dandliker PJ; Helmy R; Wood HB
J Med Chem; 2016 Mar; 59(5):1818-29. PubMed ID: 26871940
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel class of potent and selective FIXa inhibitors.
Zhang T; Andre P; Bateman TJ; Chen YH; Desai K; Ellsworth K; Geissler WM; Guo L; Hruza A; Jian T; Meng D; Parker DL; Qian X; Reichert P; Sherer EC; Shu M; Smith CJ; Sonatore LM; Tschirret-Guth R; Nolting AF; Orr R; Campeau LC; Araki K; Nishimura T; Sakurada I; Wood HB
Bioorg Med Chem Lett; 2015 Nov; 25(21):4945-4949. PubMed ID: 25978966
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel aminobenzisoxazole derivatives as orally available factor IXa inhibitors.
Sakurada I; Endo T; Hikita K; Hirabayashi T; Hosaka Y; Kato Y; Maeda Y; Matsumoto S; Mizuno T; Nagasue H; Nishimura T; Shimada S; Shinozaki M; Taguchi K; Takeuchi K; Yokoyama T; Hruza A; Reichert P; Zhang T; Wood HB; Nakao K; Furusako S
Bioorg Med Chem Lett; 2017 Jun; 27(11):2622-2628. PubMed ID: 28408226
[TBL] [Abstract][Full Text] [Related]
4. Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.
Wang S; Beck R; Blench T; Burd A; Buxton S; Malic M; Ayele T; Shaikh S; Chahwala S; Chander C; Holland R; Merette S; Zhao L; Blackney M; Watts A
J Med Chem; 2010 Feb; 53(4):1465-72. PubMed ID: 20121198
[TBL] [Abstract][Full Text] [Related]
5. Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.
Wang S; Beck R; Burd A; Blench T; Marlin F; Ayele T; Buxton S; Dagostin C; Malic M; Joshi R; Barry J; Sajad M; Cheung C; Shaikh S; Chahwala S; Chander C; Baumgartner C; Holthoff HP; Murray E; Blackney M; Giddings A
J Med Chem; 2010 Feb; 53(4):1473-82. PubMed ID: 20121197
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel tricyclic class of potent and selective FIXa inhibitors.
Meng D; Andre P; Bateman TJ; Berger R; Chen YH; Desai K; Dewnani S; Ellsworth K; Feng D; Geissler WM; Guo L; Hruza A; Jian T; Li H; Metzger J; Parker DL; Reichert P; Sherer EC; Smith CJ; Sonatore LM; Tschirret-Guth R; Wu J; Xu J; Zhang T; Campeau LC; Orr R; Poirier M; McCabe-Dunn J; Araki K; Nishimura T; Sakurada I; Hirabayashi T; Wood HB
Bioorg Med Chem Lett; 2015 Nov; 25(22):5437-43. PubMed ID: 26318999
[TBL] [Abstract][Full Text] [Related]
7. Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa.
Neuenschwander PF
Biochemistry; 2004 Mar; 43(10):2978-86. PubMed ID: 15005634
[TBL] [Abstract][Full Text] [Related]
8. Discovery of hydroxy pyrimidine Factor IXa inhibitors.
Jayne CL; Andreani T; Chan TY; Chelliah MV; Clasby MC; Dwyer M; Eagen KA; Fried S; Greenlee WJ; Guo Z; Hawes B; Hruza A; Ingram R; Keertikar KM; Neelamkavil S; Reichert P; Xia Y; Chackalamannil S
Bioorg Med Chem Lett; 2020 Aug; 30(15):127279. PubMed ID: 32527459
[TBL] [Abstract][Full Text] [Related]
9. Investigation on the binding mode of benzothiophene analogues as potent factor IXa (FIXa) inhibitors in thrombosis by CoMFA, docking and molecular dynamic studies.
Hao M; Li Y; Zhang SW; Yang W
J Enzyme Inhib Med Chem; 2011 Dec; 26(6):792-804. PubMed ID: 21381886
[TBL] [Abstract][Full Text] [Related]
10. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
[TBL] [Abstract][Full Text] [Related]
11. Na+ site in blood coagulation factor IXa: effect on catalysis and factor VIIIa binding.
Schmidt AE; Stewart JE; Mathur A; Krishnaswamy S; Bajaj SP
J Mol Biol; 2005 Jul; 350(1):78-91. PubMed ID: 15913649
[TBL] [Abstract][Full Text] [Related]
12. Correlation of factor IXa subsite modulations with effects on substrate discrimination.
Neuenschwander PF; Deadmond KJ; Zepeda K; Rutland J
J Thromb Haemost; 2012 Mar; 10(3):382-9. PubMed ID: 22212890
[TBL] [Abstract][Full Text] [Related]
13. Factor IXa as a target for anticoagulation in thrombotic disorders and conditions.
Smiley DA; Becker RC
Drug Discov Today; 2014 Sep; 19(9):1445-53. PubMed ID: 24998782
[TBL] [Abstract][Full Text] [Related]
14. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase.
Jenkins PV; Dill JL; Zhou Q; Fay PJ
Biochemistry; 2004 May; 43(17):5094-101. PubMed ID: 15109268
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood.
Ogawa S; Szlam F; Dunn AL; Bolliger D; Ohnishi T; Hosokawa K; Tanaka KA
Haemophilia; 2012 Nov; 18(6):926-32. PubMed ID: 22642581
[TBL] [Abstract][Full Text] [Related]
16. 5-Amidinoindoles as dual inhibitors of coagulation factors IXa and Xa.
Batt DG; Qiao JX; Modi DP; Houghton GC; Pierson DA; Rossi KA; Luettgen JM; Knabb RM; Jadhav PK; Wexler RR
Bioorg Med Chem Lett; 2004 Nov; 14(21):5269-73. PubMed ID: 15454209
[TBL] [Abstract][Full Text] [Related]
17. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa.
Sheehan JP; Kobbervig CE; Kirkpatrick HM
Biochemistry; 2003 Sep; 42(38):11316-25. PubMed ID: 14503882
[TBL] [Abstract][Full Text] [Related]
18. Rapid development of two factor IXa inhibitors from hit to lead.
Parker DL; Walsh S; Li B; Kim E; Sharipour A; Smith C; Chen YH; Berger R; Harper B; Zhang T; Park M; Shu M; Wu J; Xu J; Dewnani S; Sherer EC; Hruza A; Reichert P; Geissler W; Sonatore L; Ellsworth K; Balkovec J; Greenlee W; Wood HB
Bioorg Med Chem Lett; 2015 Jun; 25(11):2321-5. PubMed ID: 25937013
[TBL] [Abstract][Full Text] [Related]
19. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.
Szlam F; Luan D; Bolliger D; Szlam AD; Levy JH; Varner JD; Tanaka KA
Thromb Res; 2010 May; 125(5):432-7. PubMed ID: 20004955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
